Citius Pharmaceuticals, Inc. (CTXR): Price and Financial Metrics
GET POWR RATINGS... FREE!
CTXR Stock Price Chart Interactive Chart >
CTXR Price/Volume Stats
| Current price | $0.90 | 52-week high | $4.56 |
| Prev. close | $0.91 | 52-week low | $0.86 |
| Day low | $0.89 | Volume | 265,111 |
| Day high | $0.91 | Avg. volume | 1,692,354 |
| 50-day MA | $1.30 | Dividend yield | N/A |
| 200-day MA | $1.65 | Market Cap | 132.07M |
Citius Pharmaceuticals, Inc. (CTXR) Company Bio
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Latest CTXR News From Around the Web
Below are the latest news stories about Citius Pharmaceuticals Inc that investors may wish to consider to help them evaluate CTXR as an investment opportunity.
Maxim Group Thinks Citius Pharmaceuticals’ Stock is Going to RecoverIn a report released yesterday, Michael Okunewitch from Maxim Group initiated coverage with a Buy rating on Citius Pharmaceuticals (CTXR – Research Report) and a price target of $4.00. The company's shares closed last Wednesday at $1.62, close to its 52-week low of $1.31. According to TipRanks.com, Okunewitch is a 1-star analyst with an average return of -15.3% and a 16.7% success rate. Okunewitch covers the Healthcare sector, focusing on stocks such as Kiora Pharmaceuticals, ATAI Life Sciences, and SeqLL. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Citius Pharmaceuticals with a $6.67 average price target, representing a 304.2% upside. |
Citius Pharmaceuticals Announces FDA Acceptance of IND Application for its Phase 2b Study of Halo-Lido for the Prescription Treatment of HemorrhoidsCitius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has issued a Study May Proceed letter for Halo-Lido for the treatment of hemorrhoids. The Company is a |
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2022 Financial Results and Provides Business UpdateCitius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today reported business and financial results for the first fiscal quarter of 2022 ended December 31, 2021. |
Analysts Offer Insights on Healthcare Companies: Repare Therapeutics (RPTX), Oramed Pharmaceuticals (ORMP) and Citius Pharmaceuticals (CTXR)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Repare Therapeutics (RPTX – Research Report), Oramed Pharmaceuticals (ORMP – Research Report) and Citius Pharmaceuticals (CTXR – Research Report) with bullish sentiments. Repare Therapeutics (RPTX) In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Repare Therapeutics, with a price target of $54.00. The company's shares closed last Friday at $15.23, close to its 52-week low of $13.97. According to TipRanks. |
Citius Pharmaceuticals (CTXR) Receives a Buy from Dawson JamesIn a report issued on December 6, Jason Kolbert from Dawson James maintained a Buy rating on Citius Pharmaceuticals (CTXR – Research Report), with a price target of $10.00. The company's shares closed last Tuesday at $1.69. According to TipRanks.com, Kolbert is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -7.6% and a 35.5% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Sorrento Therapeutics, and Anavex Life Sciences. Citius Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $7.00, representing a 311.8% upside. |
CTXR Price Returns
| 1-mo | -1.11% |
| 3-mo | -42.31% |
| 6-mo | -46.43% |
| 1-year | -61.21% |
| 3-year | -30.23% |
| 5-year | -86.30% |
| YTD | -41.56% |
| 2021 | 50.98% |
| 2020 | 0.00% |
| 2019 | -1.92% |
| 2018 | -72.63% |
| 2017 | -42.94% |
Loading social stream, please wait...